FDA panel OKs Gilead’s key HIV drug Quad

Gilead Sciences ($GILD) has notched a victory in the company's campaign for Quad. The four-in-one pill for HIV won support from an FDA advisory committee Friday, bolstering the Foster City, CA-based c…
Read the full story: News